col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


31 Ergebisse       Seite 1

 [1] 
SAGE Publications: Therapeutic Advances in Neurological Disorders
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2024―Nov―08 The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study David Levitz, Yi Chao Foong, Paul Sanfilippo, Tim Spelman, Louise Rath, Angie Roldan, et al. (+35)
2 [GO] 2024―Mai―31 Comment on: Cytokines (IL1β, IL6, TNFα) and serum cortisol levels may not constitute reliable biomarkers to identify individuals with post-acute sequelae of COVID-19 Matthias Kohl
3 [GO] 2024―Mai―31 Author response to Comment on: Cytokines (IL1β, IL6, TNFα) and serum cortisol levels may not constitute reliable biomarkers to identify individuals with post-acute sequelae of COVID-19 Michael Fleischer, Fabian Szepanowski, Anne K. Mausberg, Livia Asan, Ellen Uslar, Denise Zwanziger, et al. (+3)
4 [GO] 2024―Feb―12 Cytokines (IL1β, IL6, TNFα) and serum cortisol levels may not constitute reliable biomarkers to identify individuals with post-acute sequelae of COVID-19 Michael Fleischer, Fabian Szepanowski, Anne K Mausberg, Livia Asan, Ellen Uslar, Denise Zwanziger, et al. (+3)
5 [GO] 2022―Dez―09 Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccination Simon Faissner, Neele Heitmann, Ricarda Rohling, Ulas Ceylan, Marielena Bongert, Carlos Plaza-Sirvent, et al. (+7)
6 [GO] 2022―Nov―08 Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC) Tjalf Ziemssen, Marie Groth, Benedict Rauser, Tobias Bopp
7 [GO] 2022―Okt―10 Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System Maximilian Pistor, Robert Hoepner, Andreas G.F. Hoepner, Yanan Lin, Simon Jung, Claudio L. Bassetti, et al. (+2)
8 [GO] 2022―Jul―23 Mid-term MRI evaluation reveals microstructural white matter alterations in COVID-19 fully recovered subjects with anosmia presentation Laura Pelizzari, Marta Cazzoli, Susanna Lipari, Maria Marcella Laganà, Monia Cabinio, Sara Isernia, et al. (+3)
9 [GO] 2022―Jun―25 Comment on ‘MOG antibody-associated encephalomyelitis mimicking bacterial meningomyelitis following ChAdOx1 nCoV-19 vaccination: a case report’ Josef Finsterer, Fulvio A Scorza
10 [GO] 2022―Mai―25 Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients Paraskevi C. Fragkou, Lina Palaiodimou, Maria Ioanna Stefanou, Aristeidis H. Katsanos, Vaia Lambadiari, Dimitrios Paraskevis, et al. (+9)
11 [GO] 2022―Mai―18 Corrigendum to Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
12 [GO] 2022―Apr―23 Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study Tobias Moser, Ciara O’Sullivan, Ferdinand Otto, Wolfgang Hitzl, Georg Pilz, Kerstin Schwenker, et al. (+5)
13 [GO] 2022―Mrz―12 Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response Cédric Hirzel, Denis Grandgirard, Bernard Surial, Manon F. Wider, David Leppert, Jens Kuhle, et al. (+6)
14 [GO] 2022―Jan―19 MOG antibody-associated encephalomyelitis mimicking bacterial meningomyelitis following ChAdOx1 nCoV-19 vaccination: a case report Jordi Kühne Escolà, Cornelius Deuschl, Andreas Junker, Fabian Dusse, Refik Pul, Christoph Kleinschnitz, et al. (+2)
15 [GO] 2021―Dez―08 Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19: a case report Livia Asan, Stephan Klebe, Christoph Kleinschnitz, Mark Stettner, Martin Köhrmann
16 [GO] 2021―Dez―07 Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H. Hua, Celia Oreja-Guevara, Daniel Selchen, et al. (+5)
17 [GO] 2021―Aug―14 Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab Rocco Capuano, Giovanna Donnarumma, Alvino Bisecco, Elena Grimaldi, Miriana Conte, Alessandro d’Ambrosio, et al. (+9)
18 [GO] 2021―Jul―23 Oropharyngeal swab for SARS-CoV-2 test causing atypical internal carotid artery dissection and stroke in a patient after mild COVID-19 Livia Asan, Cornelius Deuschl, Michael Forsting, Christoph Kleinschnitz, Martin Köhrmann
19 [GO] 2021―Jul―07 Persistent decline of hospitalizations for acute stroke and acute coronary syndrome during the second wave of the COVID-19 pandemic in Greece: collateral damage unaffected Christos Katsouras, Georgios Tsivgoulis, Michail Papafaklis, Theodore Karapanayiotides, Dimitrios Alexopoulos, Evangelos Ntais, et al. (+13)
20 [GO] 2021―Jul―07 The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany Daniel Richter, Simon Faissner, Dirk Bartig, Lars Tönges, Kerstin Hellwig, Ilya Ayzenberg, et al. (+2)
21 [GO] 2021―Jun―04 Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies Hela-Felicitas Petereit, Hayrettin Tumani, Uwe K. Zettl
22 [GO] 2021―Jun―04 IgG antibody titers to SARS-CoV-2 reveal a distinct efficacy of multiple sclerosis-modifying therapies to curtail lymphocyte compartments Jürgen Wienands
23 [GO] 2021―Jun―03 Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, David Magalashvili, Polina Sonis, et al. (+5)
24 [GO] 2021―Mai―31 Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies Amanda L. Piquet, John R. Corboy, Timothy L. Vollmer
25 [GO] 2021―Mai―18 Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies Christoph Friedli, Lara Diem, Helly Hammer, Nicole Kamber, Franziska Suter-Riniker, Stephen Leib, et al. (+4)
26 [GO] 2021―Apr―23 Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, David Magalashvili, Polina Sonis, et al. (+5)
27 [GO] 2021―Feb―27 Observational cohort study of neurological involvement among patients with SARS-CoV-2 infection Michael Fleischer, Martin Köhrmann, Sebastian Dolff, Fabian Szepanowski, Karsten Schmidt, Frank Herbstreit, et al. (+16)
28 [GO] 2021―Feb―05 Extensive cerebellar involvement and cognitive impairment in COVID-19-associated acute necrotizing encephalopathy Dumitru Ciolac, Igor Crivorucica, Eremei Zota, Nadejda Gorincioi, Daniela Efremova, Diana Manea, et al. (+3)
29 [GO] 2020―Dez―10 COVID-19 and cerebrovascular diseases: a comprehensive overview Georgios Tsivgoulis, Lina Palaiodimou, Ramin Zand, Vasileios Arsenios Lioutas, Christos Krogias, Aristeidis H. Katsanos, et al. (+10)
30 [GO] 2020―Jun―09 Neurological manifestations and implications of COVID-19 pandemic Georgios Tsivgoulis, Lina Palaiodimou, Aristeidis H. Katsanos, Valeria Caso, Martin Köhrmann, Carlos Molina, et al. (+12)
31 [GO] 2020―Mrz―28 Potential neurological symptoms of COVID-19 Hai-Yang Wang, Xue-Lin Li, Zhong-Rui Yan, Xiao-Pei Sun, Jie Han, Bing-Wei Zhang
 [1] 

31 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec